News

D. Medical Industries Ltd. (NASDAQ:DMED)(TASE:DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today that its subsidiary, Spring-Set Health Solutions Ltd. (formerly "Medx-Set Ltd."), has received a medical device license to market its Spring™ Universal Infusion Sets (formerly "Lighty DD Infusion Sets") in Canada.

According to the International Diabetes Federation, approximately 2.9 million diabetes patients live in Canada, constituting 11.6% of its population. That number is expected to grow considerably as the population ages. In fact, the Canadian Diabetes Association estimates that more than 9 million Canadians are currently living with either diabetes or prediabetes. Prediabetes refers to a condition where a person's blood glucose levels are higher than normal, but not yet high enough to be diagnosed as diabetes.

Efri Argaman, D. Medical's Chief Executive Officer, commented, "We continue to successfully execute on our low risk and low cost strategy of introducing and promoting the "Spring" brand name to and across various target markets - including the United States, Canada, Europe, Mexico and the BRIC countries of Brazil, Russia, India and China – via the commercial roll out of our Spring Universal Infusion Sets. Canada is an important market for us and we look forward to making this innovative product available there soon." 

About the Spring Universal Infusion Set

The Spring Universal Infusion Set is compatible with most insulin pumps currently available on the market. Going beyond the minimum requirements of subcutaneous drug delivery, the Spring Universal offers best-in-class features such as a hidden, auto-retractable needle, 360 degree connector, and smallest one-click, all-in-one inserter.

The core of the Spring Universal Infusion Set is the proprietary Detach-Detect mechanism. In the case the base of the infusion set detaches from the user's body, a blocking mechanism is triggered which, in turn, creates an occlusion. This evokes an occlusion alarm in an insulin pump. This unique feature enables exceptional reliability for continuously controlled and monitored insulin delivery, providing additional safety and peace of mind - especially for athletes and the parents of pediatric patients.